Alkeon Capital Management Reduces $5M in Alto Neuroscience, Inc. ($ANRO)
Key Points
- Alkeon Capital Management changed its Alto Neuroscience, Inc. ($ANRO) stake by 52.4% last quarter, cutting to 227,101 shares worth $4.88 million.
- Wall Street's consensus rating on $ANRO is Strong Buy and an average price target of $35.13.
- $ANRO last traded around $21.51.
Alkeon Capital Management reduced its position in Alto Neuroscience, Inc. ($ANRO) by 52.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 227,101 shares of Alto Neuroscience, Inc. after selling 250,000 shares during the quarter. Alkeon Capital Management's holdings in Alto Neuroscience, Inc. were worth $4.88 million as of its most recent filing.
Alto Neuroscience, Inc. ($ANRO) Stock
Alto Neuroscience, Inc. Earnings
Analysts Set New Price Targets
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.